Preclinical Evaluation of [ 225 Ac]Ac–Sibrotuzumab Employing a PEG 4 –Macropa Site‐Specific Chelation Strategy for Targeted Ablation of Cancer‐Associated Fibroblasts in Desmoplastic Tumors
Journal of Labelled Compounds and Radiopharmaceuticals · 2026
DOI: 10.1002/jlcr.70020 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2026. Verfasst von Syed Qaiser Shah und 3 weiteren Autor:innen. Beteiligte Einrichtung: Nuclear Medicine Research Laboratory, Institute of Chemical Sciences, University of Peshawar, Peshawar, Pakistan. Hauptthemen laut MEDLINE: Polyethylene Glycols, Actinium, Antibodies, Monoclonal, Humanized, Fibroblasts. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Higher Education Commission, Pakistan.
Abstract (Originalsprache)
Fibroblast activation protein is highly expressed in tumor‐associated fibroblasts and represents a promising stromal target for cancer therapy. Actinium‐225 ( 225 Ac) offers potent α‐emissions for targeted radiotherapy but requires exceptionally stable chelation. We report the synthesis and preclinical evaluation of the novel FAP‐targeted α‐immunoconjugate [ 225 Ac]Ac–Macropa–PEG 4 –Sibrotuzumab. Sibrotuzumab was site‐specifically modified with Macropa–PEG 4 and radiolabeled with 225 Ac under mild conditions. Radiochemical purity, serum stability, and immunoreactivity were assessed by radio‐iTLC, SEC–HPLC, and FAP + /FAP − cell assays. In vivo biodistribution and therapeutic efficacy were evaluated in NIH/3T3‐FAP + xenograft–bearing mice. The radioconjugate was obtained in 78.5% ± 2.2% yield with > 98% radiochemical purity and > 90% stability over 7 days. The immunoreactive fraction was 88.7%, and the construct demonstrated strong FAP‐specific uptake with ~30% internalization at 24 h. In vivo, [ 225 Ac]Ac–Macropa–PEG 4 –Sibrotuzumab showed high tumor accumulation (24.1 ± 1.6 %ID/g at 168 h), rapid clearance from normal tissues, and minimal bone uptake. Treatment achieved ~62% tumor growth inhibition, prolonged survival beyond 28 days, and induced partial (50%) or complete (17%) responses without systemic toxicity. These findings highlight Macropa as a robust chelation strategy and support Sibrotuzumab‐based α‐immunoconjugates for precise targeting of FAP‐positive desmoplastic tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Nuclear Medicine Research Laboratory, Institute of Chemical Sciences, University of Peshawar, Peshawar, Pakistan.
- Laboratory of Nano-Radiopharmacy, Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro, Brazil.
- Faculty of Pharmacy, Department of Radiopharmacy, Ege University, Bornova, İzmir, Türkiye.
ORCID-Profile: Syed Qaiser Shah
Förderung
- Higher Education Commission, Pakistan
Zitieren
APA
Shah, S. Q., Santos-Oliveira, R., Shabnam, M., & DeryaIlem-Ozdemir (2026). Preclinical Evaluation of [ 225 Ac]Ac–Sibrotuzumab Employing a PEG 4 –Macropa Site‐Specific Chelation Strategy for Targeted Ablation of Cancer‐Associated Fibroblasts in Desmoplastic Tumors. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.70020
Vancouver
Shah SQ, Santos-Oliveira R, Shabnam M, DeryaIlem-Ozdemir. Preclinical Evaluation of [ 225 Ac]Ac–Sibrotuzumab Employing a PEG 4 –Macropa Site‐Specific Chelation Strategy for Targeted Ablation of Cancer‐Associated Fibroblasts in Desmoplastic Tumors. Journal of Labelled Compounds and Radiopharmaceuticals. 2026. doi:10.1002/jlcr.70020
BibTeX
@article{Shah2026,
author = {Shah, Syed Qaiser and Santos-Oliveira, Ralph and Shabnam, Madeeha and DeryaIlem-Ozdemir},
title = {Preclinical Evaluation of [ 225 Ac]Ac–Sibrotuzumab Employing a PEG 4 –Macropa Site‐Specific Chelation Strategy for Targeted Ablation of Cancer‐Associated Fibroblasts in Desmoplastic Tumors},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2026},
doi = {10.1002/jlcr.70020}
}
EUVIMED